The last 3 years have seen the emergence of promising targeted therapies for the treatment
of hepatocellular carcinoma (HCC). Sorafenib has been the mainstay of treatment for a …

This article reports the various methods used to assess diaphragmatic function by
ultrasonography. The excursions of the two hemidiaphragms can be measured using two …

Hepatocellular carcinoma (HCC) is one of most prevalent cancer and is a serious healthcare
issue worldwide. Portal vein tumor thrombus (PVTT) is a frequent complication and remains …

Background Lenvatinib is a novel tyrosine kinase inhibitor that exhibits an antitumor effect
on hepatocellular carcinoma (HCC). An established strategy that involves surgery and …

Aim The aim of this study was to investigate the predictive factors of objective response rate
(ORR) and progression‐free survival (PFS), and the correlation of albumin‐bilirubin (ALBI) …

BACKGROUND Hepatocellular carcinoma (HCC) accompanied by portal vein tumour
thrombus (PVTT) presents an aggressive disease course, worsening liver function reserve …

Large tumor size and arterioportal shunt are poor prognostic factors for hepatocellular
carcinoma. Lenvatinib is a novel and potent multi-tyrosine kinase inhibitor developed in …

Aim We aimed to investigate the radiological antitumor response at 2 weeks after starting
lenvatinib for patients with advanced hepatocellular carcinoma in real‐world practice …

Simple Summary Portal hypertension (PH) and hepatocellular carcinoma (HCC) are major
complications of liver cirrhosis with a detrimental impact on patient outcomes that share …

Chronic inflammation of the native vessel wall with infiltration of lipid-laden foamy
macrophages through impaired endothelium results in atherosclerosis. Percutaneous …